A patient was diagnosed with severe immune-mediated myocarditis following treatment with sintilimab combined with gemcitabine. The patient developed immune-related myocarditis after receiving sintilimab for lung cancer immunotherapy. Several cases of myocarditis, myositis, rhabdomyolysis, hepatitis, and pneumonia associated with similar treatments have been reported in the literature (Lin Y et al., 2022; Chen X et al., 2024; Bi H et al., 2021; Xing Q et al., 2020; Xia J et al., 2024; Hu Y et al., 2023; Zhang Y et al., 2023).
